Coherus Biosciences | CHRS - Net Income


Coherus Biosciences reported $-37.64M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
AbbVie USD 4.22B 605M Sep/2026
Acadia Pharmaceuticals USD 53.52M 22.02M Sep/2026
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
ALKERMES USD 16.29M 15.79M Sep/2026
Alnylam Pharmaceuticals USD 2.17B 2B Sep/2026
Amarin USD -1.22M 6.51M Dec/2025
Amgen USD 3.86B 1.49B Sep/2026
Baxter International USD 294M 168M Sep/2026
Biogen USD 97.5M 222M Jun/2026
BioMarin Pharmaceutical USD -122.83M 167.59M Sep/2026
Bristol-Myers Squibb USD 2.16B 1.16B Sep/2026
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Eli Lilly USD 7.1B 301M Jun/2026
Fujifilm JPY 84.24B 11.58B Mar/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
Ironwood Pharmaceuticals USD 3.19M 457K Dec/2024
Merck USD 5.07B 6.4B Sep/2026
Myriad Genetics USD -7.9M 19.5M Dec/2025
Pacira USD 325.3M 320.65M Sep/2026
Perrigo USD -27.5M 102M Sep/2026
Pfizer USD 3.24B 3.49B Sep/2026
PTC Therapeutics USD 83.5M 86.3M Jun/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Sarepta Therapeutics USD -28.46M 23.57M Sep/2026
Teva Pharmaceutical Industries USD 233M 809M Sep/2026
Vertex Pharmaceuticals USD 653.6M 446.2M Sep/2026
Xencor USD -21.73M 107.19M Jun/2026
Zoetis USD 591M 100M Sep/2026